Mcp- Sf (Metoclopramide Hydrochloride Monohydrate)

Metoclopramide blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone, reducing the vomiting reflex. It also stimulates serotonin 5‑HT4 receptors, enhancing acetylcholine release that promotes coordinated contractions of the gastrointestinal tract, thereby accelerating gastric emptying.

The specific dose of Mcp- Sf is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal function. Healthcare professionals follow local prescribing information to select the appropriate amount and frequency for each indication.

Safety data for metoclopramide in pregnancy are limited, and the drug is classified as a pregnancy category with unknown risk. It should only be used if the potential benefit justifies any possible risk to the fetus. Breastfeeding mothers should consult their physician, as the drug may be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and any required import documentation.

Metoclopramide differs from other antiemetics such as ondansetron, which primarily blocks serotonin 5‑HT3 receptors. Metoclopramide’s dual action on dopamine D2 antagonism and 5‑HT4 agonism provides both central anti‑emetic effects and pro‑kinetic activity, making it useful for conditions involving delayed gastric emptying.

Mcp- Sf should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight, and extreme temperature fluctuations to maintain stability and potency.

Mcp- Sf is supplied as an injectable solution for intramuscular or intravenous administration. The route, rate, and duration of injection are determined by the prescribing clinician, who follows standard aseptic techniques and monitors the patient for any immediate adverse reactions.

Serious risks include extrapyramidal symptoms such as acute dystonia, tardive dyskinesia, and neuroleptic malignant syndrome, which can be life‑threatening. Patients should be monitored closely for muscle rigidity, fever, autonomic instability, or any signs of severe allergic reaction.

Mcp- Sf is contraindicated in patients with known hypersensitivity to metoclopramide or any component of the formulation, as well as in individuals with a history of seizure disorders, pheochromocytoma, or severe gastrointestinal obstruction. Caution is also advised for patients with Parkinson’s disease.